Encoded Therapeutics closed a $275 million Series F to advance its Dravet syndrome gene therapy into clinical trials. The bulk of the capital will fund studies of ETX101, targeting infants and children with SCN1A-positive Dravet syndrome, after the company presented interim Phase I/II data at the European Epilepsy Congress. The company is also positioning ETX301 for a planned 2027 IND filing, expanding its gene therapy scope beyond epilepsy. Encoded said it will scale internal manufacturing rather than relying solely on contract manufacturers. The raise, led by GV with an undisclosed healthcare investor, suggests investors are underwriting the company’s approach to durable seizure control and neurodevelopmental outcomes as pivotal data approaches.